ROR1 and sarcoma: The administration of 2 infusions of either IGF1R CAR or ROR1 CAR T cells derived from patient 1 into tumor-bearing mice significantly suppressed sarcoma growth at days 5, 11, 18, 25 and 32 post T-cell infusions compared to mock T-cell treated mice (p ≤ 0.01 at days 5, 11, 18, 25; p <0.01 at day 32 for IGZ; p < 0.05 at day 32 for RGZ; IGZ vs RGZ, p > 0.05 at all day points, Fig 4B and 4C).